Monday, March 16, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

UN health agency sets higher, tougher bar for air quality

The harmful health effects of air pollution kick in at lower levels than previously thought, the World Health Organization said as it set a new standard for policymakers and the public in the first update of its air quality guidelines in 15 years.

The U.N. health agency released its revised guidance as climate change is a leading topic at the U.N. General Assembly in New York. Chinese President Xi Jinping announced Tuesday that China will no longer fund power plants fired by coal, which generates several of the pollutants covered by the guidelines.

Since the last update of the WHO recommendations, better monitoring and science have cleared up the global picture about the effects of six major air pollutants on human health. According to the agency, 90% of the world’s people already live in areas with at least one particularly harmful type of pollutant.

Source: AP News

https://apnews.com/article/united-nations-general-assembly-health-climate-environment-and-nature-xi-jinping-e0684e616ceef22462b8bb5db1c2d1eb

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!